Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition and Safety in Patients With Cervical Dystonia
Completed
- Conditions
- Cervical Dystonia
- Registration Number
- NCT02175693
- Lead Sponsor
- Eisai Co., Ltd.
- Brief Summary
Investigation of the clinical condition and safety in patients with cervical dystonia
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1647
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall assessments of the improvement in the seriousness of seizures Up to 3 years Improvement is based on the 5 following elements: 1) Eminent improvement 2) Improvement 3) Improvement a little invariability 5) Exacerbation 6) It is not possible to judge
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of Botulinum Toxin Type B in treating cervical dystonia?
How does Botulinum Toxin Type B compare to A型毒素 in managing cervical dystonia symptoms?
Which biomarkers are associated with response to Botulinum Toxin Type B treatment in cervical dystonia patients?
What adverse events are commonly reported with Botulinum Toxin Type B use in cervical dystonia post-marketing surveillance?
Are there combination therapies involving Botulinum Toxin Type B for cervical dystonia and what are their outcomes?